Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: A randomised phase 3 trial

The Lancet Oncology

Volumn 12, Issue 13, 2011, Pages 1204-1213

  Elter, Thomas ^a   Gercheva Kyuchukova, Liana ^b   Pylylpenko, Halyna ^c   Robak, Tadesuz ^d   Jaksic, Branimir ^e   Rekhtman, Grigoriy ^f   Kyrcz Krzemień, Sławomira ^g   Vatutin, Mykola ^h   Wu, Jingyang ⁱ   Sirard, Cynthia ⁱ   Hallek, Michael ^a,j   Engert, Andreas ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Varna Clinic of Haematology   (Bulgaria)

^c Cherkasy Oncology Centre   (Ukraine)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

^e University of Zagreb   (Croatia)

^f Khmelnitsky Regional Hospital   (Ukraine)

^g MEDICAL UNIVERSITY OF SILESIA   (Poland)

^h DONETSK MEDICAL UNIVERSITY   (Ukraine)

ⁱ GENZYME CORPORATION   (United States)

^j UNIVERSITY OF COLOGNE   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; FLUDARABINE;

ADULT; AGED; ANEMIA; APPLICATION SITE REACTION; ARTICLE; BONE PAIN; BRONCHITIS; BRONCHOSPASM; CANCER STAGING; CANCER SURVIVAL; CARDIOPULMONARY INSUFFICIENCY; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; COUGHING; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROENTERITIS; HEMOLYSIS; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTIPLE CYCLE TREATMENT; MYCOSIS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SEPSIS; SKIN ALLERGY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; URTICARIA; VOMITING;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; NORTH AMERICA; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VIDARABINE;

EID: 82555169679     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70242-X     Document Type: Article

References (21)

1. Gribben JG How I treat CLL up front. Blood 2010, 115:187-197.
2. Maddocks KJ, Lin TS Update in the management of chronic lymphocytic leukemia. J Hematol Oncol 2009, 2:29.
3. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002, 99:3554-3561.
4. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997, 12:177-186.
5. Di GN, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001, 114:800-809.
6. Kennedy B, Rawstron A, Carter C, et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002, 99:2245-2247.
7. Elter T, Borchmann P, Schulz H, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005, 23:7024-7031.
8. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996, 87:4990-4997.
9. Pocock SJ, Simon R Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975, 31:103-115.
10. Lan KKG, Demets DL Discrete sequential boundaries for clinical trials. Biometrika 1983, 70:659-663.
11. O'Brien PC, Fleming TR A multiple testing procedure for clinical trials. Biometrics 1979, 35:549-556.
12. Hochberg Y A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988, 75:800-802.
13. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343:1910-1916.
14. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007, 25:5616-5623.
15. O'Brien S, Moore JO, Boyd TE, et al. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 2009, 27:5208-5212.
16. O'Brien S, Moore JO, Boyd TE, et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007, 25:1114-1120.
17. Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010, 28:1756-1765.
18. Hallek M State-of-the-art treatment of chronic lymphocytic leukemia. Hematology 2009, 1:440-449.
19. Clinical practice guidelines in oncology (NCCN guidelines) 2010, NCCN, National Comprehensive Cancer Network, Fort Washington, PA, (accessed Sept 30, 2011). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
20. Eichhorst B, Hallek M, Dreyling M Chronic lymphocytic leukemia: ESMO minimum clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(suppl 4):102-104. ESMO Guidelines Working Group.
21. Leone G, Pagano L, Ben-Yehuda D, Voso MT Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 2007, 92:1389-1398.